HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer

Inclusion Criteria:

1. Voluntary participation and written informed consent.

2. 18 years and older, female.

3. Pathologically diagnosed epithelial ovarian cancer, primary peritoneal cancer, orfallopian tube cancer.

4. Patients must have platinum-resistant disease

5. Be able to provide fresh or archived tumor tissue.

6. At least one measurable lesion according to RECIST v1.1.

7. Eastern Cooperative Oncology Group (ECOG) score: 0-1.

8. With a life expectancy > 12 weeks.

9. Adequate bone marrow reserve and organ function.

10. Contraception is required during the trial.

Exclusion Criteria:

1. Prior treated with TOP1 inhibitors or ADCs with TOP1 inhibitors as payload.

2. Previous or co-existing malignancies.

3. Uncontrolled pleural effusion, pericardial effusion, or abdominal effusion requiringclinical intervention.

4. Received systemic anticancer treatments 4 weeks prior to the initiation of the studytreatment.

5. Unresolved CTCAE ≥grade 2 toxicities from previous anticancer therapy.

6. History of severe hypersensitivity reactions to either the drug substances orinactive ingredients of HS-20089.

7. Any serious or uncontrolled medical disorder in the opinion of the investigator thatmay increase the risk associated with the study participation or study drugadministration.

8. Other inappropriate situation considered by the investigator.